Organigram Global Inc. · TSX:OGI
Organigram Global — Investor Presentation (July 2019)
20 slides from Organigram Global's investor presentation, Jul 8, 2019
Slide 1: Investor Presentation
Investor Presentation NASDAQ (OGI) TSX Venture (OGI)
Slide 2: Cautionary Statement
Cautionary Statement This document is current as of July 8, 2019, except where otherwise stated. The information presentation was prepared or if circumstances or management’s estimates or opinions should contained in this presentation is provided by Organigram (“OGI” or the “Company”) for change exc
Slide 3: Organigram at a Glance
• Leading licensed producer (LP) of premium quality product for Medical & Adult Recreational Markets • Market cap of ~$1.4 Billion Organigram at a • Expanding indoor, unique three-level production Glance facility in Moncton NB • Sales in all 10 provinces • Expanding global footprint with internation
Slide 4: Investment Thesis
Investment Thesis ü Lowest cost of cultivation1 of Canadian LPs, debunking claims indoor high quality production = high cost ü Increasing production capacity to 113,000 kg/yr2 with construction to be done by 2019 year-end ü One of only four Canadian LPs with distribution agreements in all 10 provinc
Slide 5: Q2 2019 Results Reflect Our Focus On Execution
Q2 2019 Results Reflect Our Focus On Execution • Record net revenue of $26.9M including first full quarter of adult-use recreational sales • $24.5M of adult-use rec sales; $2.4M of medical sales with the balance from other • Revenue from 4,248 kgs of dried flower and 5,735L litres of oil sales • Ind
Slide 6: Three Level Indoor Cultivation Technology
Three Level Indoor Cultivation Technology • Maximize footprint • Critical facets of environment controlled 6
Slide 7: Phase 4 – Expanding Indoor Production Capacity
Phase 4 – Expanding Indoor Production Capacity • Increasing target production capacity to 113,000 kg/yr1 with Phase 4a, b and c expansion at Moncton Campus facility • Construction expected to be completed by end of 2019 for total capex of ~$125M1 • Distinct competitive advantage with streamlined and
Slide 8: Phase 5 - Refurbishment for Edibles and Derivative Products
Phase 5 - Refurbishment for Edibles and Derivative Products • 56,000 square feet within existing Moncton Campus facility being refurbished for additional office space and designed 4C under EU GMP standards for: 5 4B 4A • An edibles and derivative production facility; and EDINBURGH DRIVE • Additional
Slide 9: Well-positioned for Edibles and Derivatives
Well-positioned for Edibles and Derivatives • Immediate increased extraction capacity from Valens GroWorks agreement and Phase 5 refurbishment underway • Exclusive agreement with The Green Solution, a proven market leader in the US for consulting services re: product processing and development as we
Slide 10: Innovative Vaporizer Experiences
Innovative Vaporizer Experiences • Selected as one of only four Canadian partners of PAX Era, the premium oil vaporizer created by PAX Labs, Inc. • Pax Labs, Inc. - a leader in the design and development of premium app-controlled vape technologies for cannabis • Plans to offer Edison Cannabis Co. br
Slide 11: Investment in Innovative Chocolate production line
Investment in Innovative Chocolate production line • $15 million investment commitment in a high-speed, high-capacity, fully-automated production line with capacity of up to ~4 million kg of chocolate cannabis edibles per year • OGI product development and production team with more than 25 years of
Slide 12: Organigram's Proprietary Nano-Emulsification Technology for Cannabis-Infused Beverages
Organigram’s Proprietary Nano-Emulsification Technology for Cannabis-Infused Beverages • Planning to launch dried powder formulation beverage products in early calendar 2020 in Canada • Proprietary nano-emulsion technology, developed based on analytical testing, used to create products with an initi
Slide 13: Investment in Disruptive Technology- Biosynthesis
Investment in Disruptive Technology- Biosynthesis • Investment in Hyasynth, a biotech company and leader in the field of cannaboid science and biosynthesis • Hyasynth developed a disruptive technology – biosynthesis - to naturally produce cannabinoids without growing cannabis plant • Process has the
Slide 14: Seizing the Significant Hemp-CBD Opportunity
Seizing the Significant Hemp-CBD Opportunity Global CBD • CBD increasingly being used in a number of health and wellness Market products worldwide • Agreement with 1812 Hemp, an industrial hemp research company, to secure supply and support R&D on the genetic improvement of hemp to $22B maximize yie
Slide 15: International Markets
International Markets • Alpha-cannabis®, a German company strategically • Eviana Health Corp is a publicly-listed company (CSE: positioned to serve the German medical market EHC) focused on delivering consumer health care • Strong networking ties and knowledge in the German goods using natural hemp
Slide 16: Strong Balance Sheet and Liquidity
Strong Balance Sheet and Liquidity • Cash and short-term investments of $63.4M as at Q2 2019 • Positive adjusted EBITDA for the third consecutive quarter (Q2 2019: $13.3M1) • Eliminated $49.3M in current liabilities from the balance sheet post Q2 2019 with conversion of remaining convertible debentu
Slide 17: Experienced Management Team
Experienced Management Team 17
Slide 18: Appendix
Appendix
Slide 19: Q2 2019 Financial and Operating Highlights
Q2 2019 Financial and Operating Highlights Quarter ended Feb 28, 2019 (in C$) Net Revenue $26.9M Adjusted Gross Margin %1 60% Adjusted EBITDA1 $13.3M Adjusted EBITDA Margin %1 49% Net Loss from Continuing Operations, Diluted $(0.049) Cash & Short Term Investments $63.4M Inventories $95.1M Total Asse
Slide 20: Adult Recreational Brand Portfolio
Adult Recreational Brand Portfolio 20
Organigram Global — Investor Presentation (July 2019) on 6ix